Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Carcinoma, Non-Small-Cell Lung × tremelimumab × Clear all

Phase

Status

Completed 9 Terminated 3 Recruiting 3 Active not recruiting 3 Not yet recruiting 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Mesothelioma, Malignant 3 Melanoma 2 Squamous Cell Carcinoma of Head and Neck 1 Platinum-resistant Recurrent Ovarian Cancer 1 Lung Neoplasms 1 Laryngeal Diseases 1 Kidney Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 EGFR Mutant Advanced Non Small Cell Lung Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 78 Cisplatin 77 Pemetrexed 64 Docetaxel 56 Erlotinib Hydrochloride 42 Gemcitabine 39 Paclitaxel 35 Gefitinib 33 Drug Therapy 32 Radiotherapy 31 osimertinib 26 icotinib 26 Bevacizumab 26 pembrolizumab 23 Vinorelbine 22 Nivolumab 22 anlotinib 21 camrelizumab 20 atezolizumab 15 Radiosurgery 15 Endostatins 15 aumolertinib 14 apatinib 14 endostar protein 13 durvalumab 13 sintilimab 12 Immune Checkpoint Inhibitors 9 Blood Specimen Collection 9 Surgical Procedures, Operative 8 Immunotherapy 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03975114 2023-03-24

MILES-5

National Cancer Institute, Naples

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡